...
bcli-img

Brainstorm Cell Therapeutics Inc, Common Stock

BCLI

NAQ

$2.1

-$0.15

(-6.67%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$12.83M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
38.95K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.39
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.05 L
$11.89 H
$2.1

About Brainstorm Cell Therapeutics Inc, Common Stock

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBCLISectorS&P500
1-Week Return40.62%-3.39%-3.47%
1-Month Return84.43%-3.25%-0.29%
3-Month Return-36.97%-11.61%4.5%
6-Month Return-62.51%-5.89%6.91%
1-Year Return-29.81%2.65%23.79%
3-Year Return-95.58%0.56%28.43%
5-Year Return-96.05%34.63%83.64%
10-Year Return-95.64%94.78%185.94%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue(366.00K)----[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue366.00K219.00K260.00K285.00K265.00K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":59.84,"profit":true},{"date":"2021-12-31","value":71.04,"profit":true},{"date":"2022-12-31","value":77.87,"profit":true},{"date":"2023-12-31","value":72.4,"profit":true}]
Gross Profit(732.00K)(219.00K)(260.00K)(285.00K)(265.00K)[{"date":"2019-12-31","value":-73200000,"profit":false},{"date":"2020-12-31","value":-21900000,"profit":false},{"date":"2021-12-31","value":-26000000,"profit":false},{"date":"2022-12-31","value":-28500000,"profit":false},{"date":"2023-12-31","value":-26500000,"profit":false}]
Gross Margin200.00%----[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses23.00M31.68M24.54M24.82M21.17M[{"date":"2019-12-31","value":72.6,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":77.45,"profit":true},{"date":"2022-12-31","value":78.34,"profit":true},{"date":"2023-12-31","value":66.83,"profit":true}]
Operating Income(23.00M)(31.68M)(24.54M)(24.82M)(21.44M)[{"date":"2019-12-31","value":-2300100000,"profit":false},{"date":"2020-12-31","value":-3168400000,"profit":false},{"date":"2021-12-31","value":-2453900000,"profit":false},{"date":"2022-12-31","value":-2482200000,"profit":false},{"date":"2023-12-31","value":-2143900000,"profit":false}]
Total Non-Operating Income/Expense(504.00K)(254.00K)164.00K1.09M4.24M[{"date":"2019-12-31","value":-11.9,"profit":false},{"date":"2020-12-31","value":-6,"profit":false},{"date":"2021-12-31","value":3.87,"profit":true},{"date":"2022-12-31","value":25.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(23.25M)(31.81M)(24.46M)(24.28M)(17.19M)[{"date":"2019-12-31","value":-2325300000,"profit":false},{"date":"2020-12-31","value":-3181100000,"profit":false},{"date":"2021-12-31","value":-2445700000,"profit":false},{"date":"2022-12-31","value":-2427700000,"profit":false},{"date":"2023-12-31","value":-1719200000,"profit":false}]
Income Taxes252.00K127.00K(82.00K)(545.00K)-[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":50.4,"profit":true},{"date":"2021-12-31","value":-32.54,"profit":false},{"date":"2022-12-31","value":-216.27,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(23.50M)(31.94M)(24.38M)(23.73M)-[{"date":"2019-12-31","value":-2350500000,"profit":false},{"date":"2020-12-31","value":-3193800000,"profit":false},{"date":"2021-12-31","value":-2437500000,"profit":false},{"date":"2022-12-31","value":-2373200000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(23.25M)(31.81M)(24.46M)(24.28M)(16.63M)[{"date":"2019-12-31","value":-2325300000,"profit":false},{"date":"2020-12-31","value":-3181100000,"profit":false},{"date":"2021-12-31","value":-2445700000,"profit":false},{"date":"2022-12-31","value":-2427700000,"profit":false},{"date":"2023-12-31","value":-1663200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(23.50M)(31.94M)(24.38M)(23.73M)(17.19M)[{"date":"2019-12-31","value":-2350500000,"profit":false},{"date":"2020-12-31","value":-3193800000,"profit":false},{"date":"2021-12-31","value":-2437500000,"profit":false},{"date":"2022-12-31","value":-2373200000,"profit":false},{"date":"2023-12-31","value":-1719200000,"profit":false}]
EPS (Diluted)(1.06)(1.08)(0.68)(0.66)(1.94)[{"date":"2019-12-31","value":-106,"profit":false},{"date":"2020-12-31","value":-108,"profit":false},{"date":"2021-12-31","value":-68,"profit":false},{"date":"2022-12-31","value":-66,"profit":false},{"date":"2023-12-31","value":-194,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BCLI
Cash Ratio 0.02
Current Ratio 0.05

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BCLI
ROA (LTM) -178.20%
ROE (LTM) -1121.90%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BCLI
Debt Ratio Lower is generally better. Negative is bad. 3.99
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -2.99

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BCLI
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 65.82
Price/FCF NM
EV/R 0.00
EV/Ebitda NM
PEG NM

FAQs

What is Brainstorm Cell Therapeutics Inc share price today?

Brainstorm Cell Therapeutics Inc (BCLI) share price today is $2.1

Can Indians buy Brainstorm Cell Therapeutics Inc shares?

Yes, Indians can buy shares of Brainstorm Cell Therapeutics Inc (BCLI) on Vested. To buy Brainstorm Cell Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BCLI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Brainstorm Cell Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Brainstorm Cell Therapeutics Inc (BCLI) via the Vested app. You can start investing in Brainstorm Cell Therapeutics Inc (BCLI) with a minimum investment of $1.

How to invest in Brainstorm Cell Therapeutics Inc shares from India?

You can invest in shares of Brainstorm Cell Therapeutics Inc (BCLI) via Vested in three simple steps:

  • Click on Sign Up or Invest in BCLI stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Brainstorm Cell Therapeutics Inc shares
What is Brainstorm Cell Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Brainstorm Cell Therapeutics Inc (BCLI) is $11.89. The 52-week low price of Brainstorm Cell Therapeutics Inc (BCLI) is $1.05.

What is Brainstorm Cell Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Brainstorm Cell Therapeutics Inc (BCLI) is

What is Brainstorm Cell Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Brainstorm Cell Therapeutics Inc (BCLI) is 65.82

What is Brainstorm Cell Therapeutics Inc dividend yield?

The dividend yield of Brainstorm Cell Therapeutics Inc (BCLI) is 0.00%

What is the Market Cap of Brainstorm Cell Therapeutics Inc?

The market capitalization of Brainstorm Cell Therapeutics Inc (BCLI) is $12.83M

What is Brainstorm Cell Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Brainstorm Cell Therapeutics Inc is BCLI

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top